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The strategy of using estrogen suppression to treat breast cancer led to the development of aromatase inhibitors,
including the third-generation nonsteroidal compounds anastrozole and letrozole, and the steroidal compound
exemestane. Aromatase inhibitors potently inhibit aromatase activity and also suppress estrogen levels in plasma and
tissue. In clinical studies in postmenopausal women with breast cancer, third-generation aromatase inhibitors were
shown superior to tamoxifen for the treatment of metastatic disease. Studies of adjuvant therapy with aromatase
inhibitors include (i) head-to-head studies of 5 years of the aromatase inhibitor versus 5 years of tamoxifen
monotherapy; (ii) sequential therapy of 2–3 years of tamoxifen followed by an aromatase inhibitor (or the opposite
sequence) versus 5 years of tamoxifen monotherapy; (iii) extended therapy with an aromatase inhibitor after 5 years of
tamoxifen; and (iv) sequential therapy with an aromatase inhibitor versus aromatase inhibitor monotherapy. Recent
results from the Arimidex, Tamoxifen, Alone or in Combination and Breast International Group 1–98 trials advocate
using an aromatase inhibitor upfront. This article examines the clinical data with aromatase inhibitors, following a brief
summary of their pharmacology.
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introduction
Estrogen suppression through oophorectomy was ﬁrst shown
to cause antitumor effects in premenopausal women with
breast cancer more than a century ago [1]. Later, in the 1950s,
estrogen suppression through adrenalectomy and
hypophysectomy was shown to have antitumor effects in
postmenopausal women [2–5]. At that time, the adrenal gland
was thought to be the site of estrogen synthesis in
postmenopausal women; now, we know that the adrenal gland
provides androgens (estrogen precursors) subject to peripheral
conversion (aromatization) into estrogens. Subsequent efforts
to cause estrogen suppression through ‘medical
adrenalectomy’, using glucocorticoids [6, 7], turned out to have
limited success from a clinical perspective, precipitating clinical
trials exploring different adrenal enzyme inhibitors, including
ketoconazole, for this purpose. The clinical results, however,
were not encouraging [8, 9], probably because of suboptimal
suppression of androgen secretion.
A more successful approach to estrogen suppression was
achieved with use of an unsuccessful antiepileptic
aminoglutethimide (Elliptene, later named Orimethene).
Because of its adrenal toxicity [10], this drug was used for breast
cancer treatment, revealing antitumor efﬁcacy resembling that of
other contemporary treatment options, including tamoxifen
[11–13]. Again, because of its adrenal toxicity,
aminoglutethimide was generally administered with replacement
glucocorticoids [14]. Notably, aminoglutethimide monotherapy
resulted in estrogen deprivation, resembling the effect obtained
when administered with glucocorticoids, despite a signiﬁcant
elevation of adrenal-secreted androstenedione [15].
Subsequent translational studies revealed aminoglutethimide
to act as an aromatase inhibitor [16, 17]. In parallel, the group
of Harry and Angela Brodie worked experimentally on
androstenedione derivatives as substrate-binding blockers of
the aromatase enzyme [18, 19], identifying 4-
hydroxyandrostenedione (later named formestane) [20].
The major aim in developing novel (second-generation)
aromatase inhibitors such as formestane and, later, fadrozole
(CGS 16949A) was to achieve compounds devoid of the toxic
side-effects of aminoglutethimide. However, some of these
compounds, such as anastrozole, letrozole, and exemestane
(considered third-generation compounds), subsequently
revealed more potent aromatase inhibition compared with the
ﬁrst- and second-generation compounds, and they have
completely replaced previous compounds for clinical use. This
article examines clinical results with these compounds,
following a brief summary of their pharmacology.
the aromatase enzyme and estrogen
disposition in postmenopausal women
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ligand stimulations in different tissue compartments [23–26].
Ovarian estrogen production ceases at menopause.
Postmenopausal estrogens are synthesized from circulating
androgens, mainly androstenedione, which is converted into
estrone [27, 28]. In addition, a minor pathway includes
aromatization of circulating testosterone into estradiol [29].
Plasma (and tissue) estradiol seems to have a dual origin, some
arising from the direct aromatization of testosterone, with the
rest synthesized from the reduction of estrone. While the
adrenal gland is the main contributor of circulating androgens,
conﬂicting evidence indicates a minor contribution of
circulating androgens from the postmenopausal ovary [30, 31].
Interestingly, it has been known for more than two decades
that estradiol levels are elevated in tissue, in particular breast
cancer tissue, compared with plasma [32–37]. This in general
has been attributed to local expression of the aromatase enzyme
[38, 39]. However, there may be alternative explanations. In
a recent study, we found elevated tissue concentrations of
estradiol but reduced levels of estrone in breast tumors
compared with the surrounding normal breast tissue [40].
Moreover, elevated estradiol concentrations were seen among
estrogen receptor (ER)-positive tumors only [40]. Thus, recent
results [41] suggest a strong correlation between intratumor
estradiol levels and plasma estradiol but also intratumoral ER
expression as well as negative to dehydrogenase 2 but positive
to dehydrogenase 7 levels, indicating that intratumor estradiol
may arise from estrone reduction. Such a hypothesis actually
ﬁts well with observations that circulating estrogen levels
correlate with intratumoral expression of estrogen-regulated
genes [42] and subsequent breast cancer risk [43] as well as to
time to relapse [44] in hormone-sensitive breast cancer. These
ﬁndings may have signiﬁcant implications in future therapeutic
strategies aiming at tumor-speciﬁc manipulation of estrogen
synthesis.
pharmacology and in vitro aromatase
inhibition
Aromatase inhibitors may be separated into two distinct classes:
steroidal and nonsteroidal compounds. Characteristically,
steroidal inhibitors bind to the substrate-binding site in an
irreversible manner [45], leading to degradation of the protein–
drug complex. The exact binding mechanism is still a subject of
research [46]. The two steroidal compounds extensively
evaluated for clinical use were the second-generation
compound formestane (4-hydroxyadrostenedione) and the
third-generation compound exemestane.
In contrast to steroidal inhibitors, nonsteroidal compounds
bind to the P450 site of the aromatase complex [45]. These
compounds may be divided into compounds of the
aminoglutethimide class and those of the imidazole/triazole
class. Apart from aminoglutethimide itself, the
aminoglutethimide class includes compounds such as
rogletimide [47] as well as the separate L-enantiomer of
aminoglutethimide [48]; due to toxicity, none of these
compounds are in clinical use. The imidazole/triazole class
includes the second-generation compound fadrozole [49, 50]
and the third-generation compounds anastrozole and letrozole.
In vitro evaluations of aromatase inhibitors have been carried
out using placental as well as ovarian microsomal fractions
[51], breast cancer homogenates, and breast-derived ﬁbroblasts
[52]. Brieﬂy, the results may be summarized as follows: all
second- and third-generation compounds express a much
higher potency compared with aminoglutethimide in
experimental systems [52]. Second, the relative potency in
general is higher for compounds of the imidazole/triazole class
compared with steroidal compounds [52], consistent with the
need for higher drug doses of the latter compounds in the
clinic. Third, comparing the third-generation triazole
derivatives anastrozole and letrozole, letrozole showed
a signiﬁcantly higher potency with respect to aromatase
inhibition in breast homogenates and breast ﬁbroblasts [52].
Finally, while in general the novel third-generation compounds
possess a higher potency compared with the second-generation
compounds, some in vitro studies actually revealed a somewhat
higher potency for fadrozole compared with letrozole [53]. This
underscores the fact that in vivo efﬁcacy depends not on direct
potency alone but is also subject to inﬂuence by other
parameters, in particular pharmacokinetics.
aromatase inhibition in vivo and plasma
and tissue estrogen suppression
A major problem with evaluating the biochemical potency of
aromatase inhibitors in vivo has been the problem of method
sensitivity. Over the years, some groups, in particular the team
headed by Professor Mitch Dowsett at the Royal Marsden
Hospital and our team, have consistently worked at improving
radioimmunoassays for this purpose [54–56]. While others
[57] have developed gas chromatography/tandem mass
spectrometry methods, so far such methods have been available
for estradiol only and not for estrone or estrone sulfate, and the
detection limit remains above what may be optimally achieved
by radioimmunoassays. With a recent improved
radioimmunoassay revealing detection limits for plasma
estradiol, estrone, and estrone sulfate of 0.67, 1.14, and 0.55
pM, respectively [56], based on mean plasma estrogen values in
postmenopausal women (15, 80, and 400 pM, respectively),
in theory, we may detect an average suppression of plasma
estradiol, estrone, and estrone sulfate of 95.5%, 98.6%, and
99.9%, respectively. Notably, reanalyzing [37] plasma samples
from patients treated sequentially with letrozole and
anastrozole [58] using these improved assays, plasma estradiol
levels were still suppressed below detection limit in 11 of 12
patients during treatment with letrozole and 5 of 12 patients on
anastrozole; similar ﬁndings have been recorded by others [54].
For steroidal compounds such as exemestane, because of their
steroid chemical structure and the potential for minor
metabolites to interact in the radioimmunoassays, plasma
estrogen analysis requires pre-puriﬁcation of the samples with
use of high-pressure liquid chromatography (HPLC) [59] or
related methods.
A more sensitive method is to assess in vivo aromatase
inhibition with tracer techniques [60, 61]. In a joint program
with the Royal Marsden Hospital, aminoglutethimide, together
with the different second- and third-generation compounds in
clinical use was systematically examined with respect to
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a distinct difference was observed between aminoglutethimide
and the second-generation compounds, causing aromatase
inhibition in general not exceeding 90%, and the novel third-
generation compounds anastrozole, exemestane, and letrozole,
causing 98% inhibition or better.
While these studies were conducted by the same investigators
and with use of standardized methods, one should be careful
making indirect comparisons within the group of third-
generation inhibitors. Notably, there is substantial
interindividual variation with respect to the degree of
aromatization. Interestingly, when letrozole and anastrozole were
compared in the same patients in a crossover study [58],
letrozole was found to be a more potent inhibitor of in vivo
aromatization in all patients; subsequent plasma estrogen
analysis also revealed that letrozole treatment resulted in
signiﬁcantly better suppression for each estrogen fraction [37].
In addition, comparing the results of a study with letrozole and
a similar study with anastrozole that used the same methods to
analyze tissue estrogens, highly sensitive radioimmunoassay
following HPLC puriﬁcation showed greater suppression of each
tissue estrogen fraction with letrozole than with anastrozole
(97.6% versus 89.0% for estradiol, 90.7% versus 83.4% for
estrone, and 90.1% versus 72.9% for estrone sulfate) [36, 37].
All in all, these ﬁndings indicate that exemestane,
anastrozole, and letrozole are the most potent aromatase
inhibitors, with a somewhat higher potency for letrozole 2.5 mg
daily compared with anastrozole 1 mg daily. No conclusion
may be drawn regarding exemestane potency versus the other
two compounds. The potential contribution of aromatase
inhibitor potency to the lack of cross-resistance between
steroidal and nonsteroidal compounds is discussed later.
clinical use of aromatase inhibitors in
metastatic disease
Implementing treatment with aromatase inhibitors in the
adjuvant setting was not possible without careful and
systematic evaluation of their efﬁcacy and toxicity in metastatic
disease. As these investigations were conducted more than
a decade ago, the results of these studies are provided as
supplementary data, available at Annals of Oncology online.
presurgical treatment of primary breast
cancer
Presurgical treatment (previously termed neoadjuvant therapy)
has gained increasing use in breast cancer. While most studies
have explored the use of chemotherapy in this setting, studies
have also evaluated novel third-generation aromatase inhibitors
as presurgical treatment based on the encouraging results
obtained in the metastatic as well as in the adjuvant setting.
To date, the results of four studies in postmenopausal women
comparing the efﬁcacy of third-generation aromatase inhibitors
with tamoxifen have been reported (Table 2) [68–71]. While the
study with exemestane suggests a beneﬁt compared with
tamoxifen, the number of patients is too small to allow for
statistical conclusions. Notably, the two studies with anastrozole,
Table 1. Inhibition of aromatization by aminoglutethimide, second-generation aromatase inhibitors, and third-generation aromatase inhibitors
Aromatase inhibitor Dose Percent inhibition of
aromatization (mean)
Aminoglutethimide class
Aminoglutethimide [62] 1000 mg qd 90.56
Rogletimide [62] 200 mg b.i.d. 50.6
Rogletimide [62] 400 mg b.i.d. 63.5
Rogletimide [62] 800 mg b.i.d. 73.8
Second-generation aromatase inhibitors
Fadrozole (CGS 16949A) [49] 1 mg b.i.d. 82.4
Fadrozole (CGS 16949A) [49] 2 mg b.i.d. 92.6
Formestane (4-hydroxyandrostendione) [63] 250 mg every 14 days 84.8
Formestane (4-hydroxyandrostendione) [63] 500 mg every 14 days 91.9
Formestane (4-hydroxyandrostenedione) [64] 125 mg qd 62.3
Formestane (4-hydroxyandrostenedione) [64] 125 mg b.i.d. 70.0
Formestane (4-hydroxyandrostenedione) [64] 250 mg qd 57.3
Formestane (4-hydroxyandrostenedione) [65] 500 mg weekly 91.3
Formestane (4-hydroxyandrostenedione) +
aminoglutethimide [65]




Anastrozole [66] 1 mg qd 96.7
a
Anastrozole [66] 10 mg qd 98.1
a
Anastrozole [58] 1 mg qd 97.3
a
Letrozole [58] 2.5 mg qd >99.1
a
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a signiﬁcant beneﬁt for anastrozole compared with tamoxifen
[68, 69]. In contrast, letrozole was shown to signiﬁcantly
improve the response rate compared with tamoxifen [70].
adjuvant therapy
Adjuvant studies on aromatase inhibitors may be separated into
four categories (Figure 1): (i) head-to-head comparison,
evaluating 5 years of treatment with the novel agent versus 5
years on tamoxifen; (ii) sequential therapy, comparing 2–3
years with either tamoxifen followed by the aromatase inhibitor
or the opposite sequence, for a total of 5 years, with 5 years of
tamoxifen; (iii) extended therapy, evaluating the beneﬁts of
adding extended treatment with an aromatase inhibitor in
patients already exposed to tamoxifen treatment of 5 years; and
(iv) comparing use of the novel aromatase inhibitor
administered sequentially with 5 years of aromatase inhibitor
monotherapy. It should be noted that the four-armed Breast
International Group (BIG) 1–98 study addresses all these topics
except extended therapy.
head-to-head comparison
The ﬁrst study evaluating an aromatase inhibitor in the
adjuvant setting was not Arimidex, Tamoxifen, Alone or in
Combination (ATAC) but a study conducted by the
Royal Marsden Hospital, London, comparing
aminoglutethimide monotherapy with placebo, each
administered for 2 years [72]. Only 354 patients were included,
Table 2. Studies of presurgical treatment with aromatase inhibitors
compared with tamoxifen or chemotherapy





Anastrozole versus tamoxifen versus combination [68]
Anastrozole 113 37% 0.87
Tamoxifen 108 36%
Anastrozole + tamoxifen 109 39% 0.61
Anastrozole versus tamoxifen [69]
Anastrozole 228 50.0 0.37
Tamoxifen 223 46.2
Letrozole versus tamoxifen [70]
Letrozole 154 55% <0.001
Tamoxifen 170 36%
Exemestane versus tamoxifen [71]
Exemestane 25 76.3% 0.05
Tamoxifen 75 40.0%
Figure 1. Design of adjuvant aromatase inhibitor trials. ABCSG, Austrian Breast and Colorectal Cancer Study Group; AG, aminoglutethimide; ANA,
anastrozole; ARNO, Arimidex–Nolvadex; ATAC, Arimidex, Tamoxifen, Alone or in Combination; EXE, exemestane; IES, Intergroup Exemestane Study;
ITA, Italian Tamoxifen Anastrozole; LET, letrozole; NSABP, National Surgical Adjuvant Breast and Bowel Project; R, randomization; TAM, tamoxifen;
TEAM, Tamoxifen, Exemestane Adjuvant Multicenter.
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the two arms.
The ATAC study compared 5 years of tamoxifen
monotherapy with anastrozole monotherapy. In addition,
a third arm used the two drugs in combination [73]. While
anastrozole signiﬁcantly improved disease-free survival (DFS)
compared with tamoxifen monotherapy (Table 3),
interestingly, combined therapy provided no beneﬁt compared
with tamoxifen monotherapy. Notably, previous studies
combining tamoxifen and aminoglutethimide did not improve
treatment outcome compared with tamoxifen monotherapy in
metastatic disease [87–91].
Results from ATAC at a median 100 months of follow-up
[75] are shown in Table 3. Anastrozole signiﬁcantly improved
DFS [hazard ratio (HR) 0.90, P = 0.25 in the intent-to-treat
(ITT) population; HR 0.85, P = 0.003 in the hormone receptor
(HR)-positive population]. However, no improvement in
overall survival (OS) has been reported to date (HR 1.00, P =
0.99 in the ITT population; HR 0.97, P = 0.7 in the HR-positive
population).
The second study reporting a head-to-head comparison with
an aromatase inhibitor was BIG 1–98, comparing letrozole with
tamoxifen as monotherapy and as sequential treatments. While
the ﬁrst report at a median of 25.8 months of follow-up
compared all patients receiving tamoxifen initially with all
patients receiving letrozole initially and censored observations
in the sequential treatment arms (C and D) at time of crossover
(Figure 1) [76], a second report compared patients allocated
with the monotherapy arms (A and B) only at a median follow-
up of 51 months [77]. As seen in Table 3, the two different
comparisons revealed almost identical results. In the various
analyses of BIG 1–98, letrozole improved DFS to a degree
resembling that observed with anastrozole. However, in the
most recent follow-up in the monotherapy arms (median 76
months), there was also a statistically nonsigniﬁcant trend in
favor of a survival beneﬁt with letrozole (HR 0.87, P = 0.08)
[78], in contrast with the lack of improved survival observed
with anastrozole in ATAC. It should be noted that the BIG 1–98
ITT analysis was biased against letrozole as 612 patients opted
to cross over from tamoxifen to letrozole following the
unblinding of the tamoxifen arm in 2005 [78]. An inverse
probability of censoring weighted analysis, which corrects for
bias due to nonadherence to randomized treatment, showed
a signiﬁcant survival beneﬁt with letrozole compared with
tamoxifen (HR 0.83, 95% conﬁdence interval 0.71–0.97) [78].
It is conceivable that the survival beneﬁt observed with letrozole
at 76 months’ median follow-up is the result of the early
reduction in the risk of distant metastases with letrozole versus
tamoxifen observed early on at a median follow-up of 25.8
months [76].
The Tamoxifen, Exemestane Adjuvant Multicenter (TEAM)
trial, another study comparing tamoxifen with an aromatase
inhibitor, was initially designed to compare 5 years of
monotherapy with either exemestane or tamoxifen [79].
However, based on favorable results from the Intergroup
Exemestane Study (IES), a sequential study with exemestane, the
study design for TEAM was amended to compare
exemestane monotherapy with sequential therapy comprising
2.5–3 years of tamoxifen followed by exemestane (Figure 1)
[79]. Results from the monotherapy arm analysis from TEAM
at 2.75 years of median follow-up showed no signiﬁcant
beneﬁt in DFS with exemestane compared with tamoxifen
(Table 3) [79].
sequential therapy
The ﬁrst sequential study was a small trial of tamoxifen
followed by aminoglutethimide compared with tamoxifen
monotherapy in 380 patients [92]. There was no signiﬁcant
difference in event-free survival, although a difference was
observed in OS favoring aminoglutethimide.
Sequential trials of third-generation aromatase inhibitors (a
total of ﬁve) include three [Italian Tamoxifen Anastrozole
(ITA), Austrian Breast and Colorectal Cancer Study Group
(ABCSG)-8, and Arimidex–Nolvadex (ARNO 95)] evaluating
sequential use of 2–3 years of tamoxifen followed by
anastrozole for a total of 5 years [80, 81], the IES evaluating
sequential treatment with 2–3 years of tamoxifen followed by
exemestane for a total of 5 years [82], and the two sequential
arms of the BIG 1–98 study evaluating 2 years of
tamoxifen followed by 3 years of letrozole or the opposite
sequence [78].
For BIG 1–98, results have been reported for the comparison
between the monotherapy arms and for the comparison
between each of the sequential options and letrozole
monotherapy [78], but to date, the results comparing sequential
treatment with tamoxifen monotherapy have not been reported.
Results from the other sequential studies (ITA, ABCSG-8,
ARNO 95, and IES) are summarized in Table 3.These studies
demonstrated improved DFS for sequential administration of
tamoxifen followed by the aromatase inhibitor compared with
tamoxifen monotherapy. However, some differences regarding
study design should be mentioned. Although the Austrian and
German studies (ABCSG-8 and ARNO 95) were reported
together [81], the studies differ in that the Austrian study,
similar to BIG 1–98 [76], randomized patients upfront (before
beginning any endocrine therapy). In contrast, the German
study, similar to the IES [82] and the Italian study [80]
randomized patients after 2 years on tamoxifen therapy.
However, assuming that the number of relapses was reasonably
well balanced in the two arms starting with tamoxifen for 2
years, this difference should have little impact on the HR
comparison following switching. It is possible, though, that the
German and Italian studies as well as the IES selected for
a patient population that was more endocrine responsive.
A second issue relates to OS. While the combined result of the
German–Austrian studies so far has revealed no statistical
improvement regarding OS [81], a survival beneﬁt was shown
whentheresultsfromthesestudieswerecombinedwiththeresults
from the Italian trial [93]. This combined analysis, however, has
been debated on statistical grounds [94]. In the IES, OS was
reportedafterblocksfromER-unknowntumorswereanalyzedfor
ER expression. Following the exclusion of 122 tumors shown
actually to be ER negative, a follow-up report at a median of
55.7 months revealed statistically improved survival
(P = 0.04, when adjusted for potential confounders) in the
combined group of ER-positive and (still) ER-unknown
tumors [83].
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So far, three studies have reported on extended adjuvant
therapy with an aromatase inhibitor following the completion
of 5 years of tamoxifen (Figure 1): the MA.17 trial evaluating
letrozole for 5 years in comparison with placebo [84, 95],
the open-labeled Austrian ABCSG-6a trial evaluating
anastrozole for 3 years in comparison with no treatment [85],
and the National Surgical Adjuvant Breast and Bowel
Project (NSABP) B-33 trial evaluating exemestane in
comparison with placebo [86]. T h er e s u l t sa r es u m m a r i z e di n
T a b l e3 .W h i l et h eM A . 1 7a n dt h eA B C S G - 6 as t u d yr e p o r t e d
signiﬁcantly improved DFS and recurrence-free survival,
respectively, by adding the aromatase inhibitor after 5 years
on tamoxifen, a nonsigniﬁcant trend was observed in the
NSABP B-33 study. The most likely reason for this
disparity was early termination of patient recruitment in
NSABP B-33 (only 1598 of a total planned number of 3000
patients were accrued due to the positive results reported
from study MA.17). An improvement in OS was noted in
M A . 1 7o nl o n g e rf o l l o w - u p( m e d i a n3 0m o n t h s )f o rn o d e -
positive but not for node-negative patients [84], most
likely because of a smaller number of events among node-
negative patients.
sequential treatment versus aromatase
inhibitor monotherapy
So far, the only results published for the comparison of
sequential therapy with aromatase inhibitor monotherapy are
from BIG 1–98 [78]. While results from the TEAM trial at
a median 5.1 years of follow-up showed no signiﬁcant
difference in DFS with sequential tamoxifen followed by
exemestane compared with exemestane monotherapy, the
results so far have been presented only at a congress [96].
Importantly, the BIG 1–98 study evaluated both tamoxifen
followed by letrozole and letrozole followed by tamoxifen. At
a median follow-up of 71 months, no signiﬁcant difference with
respect to DFS was recorded between any of the sequential
treatment regimens and letrozole monotherapy (Figure 2) [78].
However, while no difference (so far) was seen between
letrozole for 2 years followed by tamoxifen and letrozole
monotherapy, 2 years of tamoxifen upfront was associated with
an increased risk of relapse during that initial time interval.
Interestingly, results from the ATAC study [97] as well as from
the monotherapy comparison of BIG 1–98 support the
conclusion that aromatase inhibition upfront is beneﬁcial. This
observation may have a biological rationale. While
conventional wisdom considered early relapses (within 2 years
Table 3. Studies of third-generation aromatase inhibitors as adjuvant therapy




ATAC [73] ANA versus TAM 6241 33.3 HR 0.78
a, P = 0.005 Not analyzed Not analyzed
ATAC [74] ANA versus TAM 6241 68 HR 0.83
a, P = 0.005 HR 0.84
a, P = 0.06 HR 0.97
a, P = 0.7
ATAC [75] ANA versus TAM 6241 100 HR 0.85
a, P = 0.003 HR 0.84
a, P = 0.022 HR 0.97
a, P = 0.7
BIG 1–98 [76] LET versus TAM 8010 25.8 HR 0.81, P = 0.003 HR 0.73, P = 0.001 HR 0.86, P = 0.16
BIG 1–98 [77] LET versus TAM 4922 51 HR 0.82, P = 0.007 HR 0.81, P = 0.03 HR 0.91, P = 0.35
BIG 1–98 [78] LET versus TAM 4922 76 ITT: HR 0.88, P = 0.03;
IPCW: HR 0.85, 95% CI
0.76–0.96
HR 0.85, P = 0.05 ITT: HR 0.87, P = 0.08;
IPCW: HR 0.83, 95% CI
0.71–0.97
TEAM [79] EXE versus TAM 9766 33 HR 0.89, P = 0.12 HR 0.81, P < 0.03 Not analyzed
(88 EXE versus
82 TAM)
ITA [80] ANA versus TAM 448 36 HR 0.35, P = 0.001 HR 0.49, P = 0.06 Not analyzed
ABCSG-8/ARNO
95 [81]
ANA versus TAM 3224 28 HR 0.60
b, P = 0.0009 HR 0.61, P = 0.0067 P = 0.16
IES [82] EXE versus TAM 4742 30.6 HR 0.68, P < 0.001 Not analyzed HR 0.88, P = 0.37
IES [83] EXE versus TAM 4742 55.7 HR 0.76, P = 0.0001 HR 0.83, P = 0.03 HR 0.85, P = 0.08
MA.17 [84] LET versus PLA 5187 30 HR 0.58, P < 0.001 HR 0.60, P = 0.002 HR 0.82, P = 0.3
ABCSG-6a [85] ANA versus no treatment 856 62.3 HR 0.62
c, P = 0.031 HR 0.53, P = 0.034 HR 0.89, P = 0.570





ABCSG, Austrian Breast and Colorectal Cancer Study Group; ANA, anastrozole; ARNO, Arimidex–Nolvadex; ATAC, Arimidex, Tamoxifen, Alone or in
Combination; BIG, Breast International Group; CI, conﬁdence interval; DDFS, distant disease-free survival; DFS, disease-free survival; EXE, exemestane; HR,
hazard ratio; IES, Intergroup Exemestane Study; IPCW, inverse probability of censoring weighted; ITA, Italian Tamoxifen Anastrozole; ITT, intent-to-treat;
LET, letrozole; NS, not signiﬁcant; NSABP, National Surgical Adjuvant Breast and Bowel Project; OS, overall survival; PLA, placebo; RR, relative risk; TAM,
tamoxifen; TEAM, Tamoxifen, Exemestane Adjuvant Multicenter; TTDR, time to distant recurrence.
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[93], these observations were recorded among patients having
tamoxifen treatment. Notably, ﬁndings from the primary
treatment 024 protocol suggested an improved response rate to
letrozole among patients with tumor expressing intermediate-to-
low expression levels of the ER [98].
In contrast, no difference regarding outcome was seen for
sequential treatment with 2 years of letrozole followed by
tamoxifen compared with letrozole monotherapy (Figure 2).
This ﬁnding, however, should be interpreted carefully,
considering the limited duration of follow-up.
meta-analysis of efﬁcacy
Particular attention should be directed at the recent meta-
analysis integrating data of the individual trials [99]. Upfront
therapy (ATAC and BIG 1–98 combined) showed that use of an
aromatase inhibitor caused a signiﬁcant (P < 0.00001) 2.9%
absolute reduction in the 5-year relapse rate, with
a corresponding nonsigniﬁcant 1.1% decrease of breast cancer
mortality. It is noteworthy that while no statistically signiﬁcant
difference between anastrozole and letrozole was observed,
a trend favoring letrozole was recorded with respect to breast
cancer as well as total mortality rate. Similarly, no difference
was recorded regarding the efﬁcacy of anastrozole versus
exemestane for sequential treatment (3.1% absolute reduction
in relapse rate 3 years after divergence of the aromatase
inhibitor and tamoxifen arm, P < 0.00001). However,
signiﬁcantly improved survival was recorded with the use of
aromatase inhibitors versus tamoxifen (absolute reduction of
0.7%, P = 0.02). Therefore, this analysis conﬁrmed the
beneﬁcial effect of treatment with third-generation aromatase
inhibitors versus tamoxifen either given as monotherapy or
applied sequentially. While the analysis conﬁrmed any potential
difference between individual compounds (if any) to be minor,
longer follow-up is needed to fully address potential effects on
long-term survival [99].
side-effects
The fact that a large number of breast cancer patients are
becoming long-term survivors increases the focus on potential
side-effects of treatments. With aromatase inhibitors, major
concerns relate to detrimental effects on bone and lipid
metabolism, which may enhance the risk of osteoporotic
fracture rates as well as cardiovascular disease.
Osteoporosis is a major health threat to the aging female
population in most countries. The lifetime risk for a hip
fracture among western European and USA females is in the
range of 15%–20%; for reasons not completely understood, in
some countries, such as Sweden, it may exceed 25% [100].
Osteoporotic fractures are associated with a signiﬁcant excess
mortality [101]. Regarding the effects of aromatase inhibitors
on bone metabolism, it is well established that all aromatase
inhibitors moderately enhance bone loss. While this effect has
been shown in comparison with tamoxifen [102, 103], it should
be noted that tamoxifen exhibits anabolic effects on bone in
postmenopausal women, resulting in increased bone mineral
density [104]. However, evaluating the effects of exemestane
[105] as well as letrozole [106] versus placebo on bone
metabolism has shown a moderate loss in bone density with
these aromatase inhibitors. Notably, while ongoing treatment
with an aromatase inhibitor is associated with increased bone
fracture rate [77, 83, 103] in comparison with tamoxifen,
detrimental effects of aromatase inhibitors on bone metabolism
are reversible upon terminating the drug [107]. With
encouraging results from the ABCSG, which suggest that
zoledronic acid may completely prevent aggravated bone loss
even among premenopausal women with endocrine-responsive
early breast cancer exposed to ovarian ablation and anastrozole
in concert [108], and from the Zometa-Femara Adjuvant
Synergy Trial [Z-FAST (United States) and ZO-FAST (global)]
clinical trial program showing the prevention of bone loss with
upfront versus delayed zoledronic acid in postmenopausal
women with early breast cancer receiving letrozole [109],
detrimental effects on bone metabolism appear to be
completely preventable using regular bone mineral density
assessment, vitamin D and calcium supplementation, and
bisphosphonates.
A second major concern associated with estrogen
suppression is the potential for detrimental effects on lipid
metabolism as well as homocysteine [110]. As for the latter,
recent evidence suggests that plasma homocysteine may not be
Figure 2. Cumulativeincidenceofbreastcancerrecurrenceinthesequential
treatmentanalysisoftheBreastInternationalGroup1–98trialatamedian71
months of follow-up. A: T - L versus L, B; L - T versus L. Reprinted with
permission [78]. Copyright  2009 Massachusetts Medical Society.
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While for decades it was believed that estrogen replacement
therapy was protective regarding the risk of cardiovascular
events in postmenopausal women, recent evidence has found
no reduction in cardiovascular risk with hormone replacement
therapy despite conﬁrming an 10%–15% elevation in
high-density lipoprotein cholesterol levels [112–116]. With
regard to the effects of aromatase inhibitors on plasma lipid
levels, studies conducted on nonfasting samples or on patients
with metastatic disease, who often suffer from metabolic
disturbances [117], are unreliable [118]. In the two studies
evaluating the effects of an aromatase inhibitor versus placebo
in early disease, exemestane [105] as well as letrozole [119] had
minor effects on plasma lipid levels. Based on the rates of
cardiovascular events in the phase 3 trials comparing aromatase
inhibitors with tamoxifen or placebo in the adjuvant setting
(Table 4), there is no substantial evidence suggesting
detrimental effects of aromatase inhibitors with respect to
cardiovascular morbidity and mortality in early breast cancer.
A third type of aromatase inhibitor-associated side-effect now
receiving more attention is musculoskeletal joint pain and
stiffness. While most patients have moderate disturbances, there
is evidence that 20% of the patient population does not adhere
to prescribed therapy with aromatase inhibitors [120], and
musculoskeletal and joint paint may be responsible for at least
50% of these withdrawals [121]. Recently, Belgian investigators
reported synovial deposits detectable by magnetic resonance
imaging scans among patients suffering tendon and joint pain
while taking aromatase inhibitors [122]. While results from the
Anastrozole versus Letrozole, an Investigation of Quality Of Life
and Tolerability study, a randomized trial of postmenopausal
women who received 12 weeks of letrozole followed by 12 weeks
of anastrozole or vice versa, suggest that switching aromatase
inhibitors may alleviate joint symptoms in some women, >50%
of patients who experienced joint symptoms on one aromatase
inhibitor did not experience them on the other aromatase
inhibitor [123]; more data are needed to address this topic.
aromatase inhibition—state of the art
and way forward
Recent head-to-head data from BIG 1–98 comparing sequential
treatment with monotherapy [78], combined with ﬁndings in
the ATAC [74] and BIG 1–98 trials that treatment with an
aromatase inhibitor reduces relapses compared with tamoxifen
during the ﬁrst 2 years of treatment, advocate using an
aromatase inhibitor upfront. While no difference in outcome
was recorded between patients receiving letrozole
monotherapy, and those receiving letrozole initially then
switching to tamoxifen after 2 years, these data need to be
interpreted carefully due to the limited duration of follow-up
from the time of switching. While previous data revealed no
beneﬁt of extending tamoxifen treatment beyond 5 years in the
adjuvant setting [124], we do not know the optimal duration of
treatment with an aromatase inhibitor or whether switching to
tamoxifen or perhaps even estrogen treatment after a certain
time period may be beneﬁcial.
Regarding estrogen suppression, similar to what has been
recorded with tamoxifen, there is reason to believe that many
tumors developing acquired resistance to aromatase inhibitors
may still be sensitive to endocrine manipulation. Based on
experimental evidence, suggesting that long-term estrogen
deprivation may sensitize breast cancer cells to estrogen
stimulation [125, 126], we implemented treatment with
diethylstilbestrol for patients developing resistance to
aromatase inhibitors in the metastatic setting [127]. Thirty
percent of patients achieved an objective response, suggesting
the potential of sequential endocrine manipulation of
hormone-sensitive tumor cells [128–130].






ATAC [75] 100 Myocardial infarction: ANA
34 (annual rate 0.27)
versus TAM 33 (annual
rate 0.27) on treatment;
ANA 26 (annual rate 0.28)
versus TAM 28 (annual
rate 0.30) off treatment
BIG 1–98 [78] 71
a Cardiac events (any grade):
LET-containing regimens
6.1%–7.0% versus TAM
5.7% (P = 0.45)
TEAM [79] 33 Myocardial ischemia/
infarction: EXE 41 (0.8%)
versus 31 (0.6%) TAM
(P = NS)
Cardiac deaths: EXE 18
(0.4%) versus TAM 11
(0.2%) (P = NS)
IES [83] 55.7 Cardiovascular events: EXE
382 (16.5%) versus TAM
350 (15.0%) (P = 0.16)
ITA [80] 36 Cardiovascular disease events:
ANA 16 (7.9%) versus
TAM 14 (9.3%) (P = 0.4)
ABCSG-8/ARNO 95 [81] 28 Myocardial infarction: ANA 3
(<1%) versus TAM 2
(<1%) (P = 1.0)
MA.17 [84] 30 Cardiovascular disease events:
LET 149 (5.8%) versus
PLA 144 (5.6%) (P = 0.76)
ABCSG6a [85] 62.3 Myocardial infarction: ANA 1
(0.3%) versus no further
treatment 0
NSABP B-33 [86] 30 Not reported
aSequential treatment analysis.
ABCSG, Austrian Breast and Colorectal Cancer Study Group; ANA,
anastrozole; ARNO, Arimidex–Nolvadex; ATAC, Arimidex, Tamoxifen,
Alone or in Combination; EXE, exemestane; BIG, Breast International
Group; IES, Intergroup Exemestane Study; ITA, Italian Tamoxifen
Anastrozole; LET, letrozole; NS, not signiﬁcant; NSABP, National Surgical
Adjuvant Breast and Bowel Project; PLA, placebo; TAM, tamoxifen; TEAM,
Tamoxifen, Exemestane Adjuvant Multicenter.
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may provide an advantage over the others. Comparing the
two nonsteroidal aromatase inhibitors anastrozole and
letrozole, there is substantial evidence that letrozole causes
more potent in vivo aromatase inhibition [58] and plasma
[37, 54, 58] and tissue [37] estrogen suppression. While data
in the second-line metastatic setting are not straightforward,
notably the one randomized study comparing letrozole
versus anastrozole showed no signiﬁcant differences in time
to progression, the primary end point. However, letrozole
was signiﬁcantly superior to anastrozole in overall response
rate (ORR, secondary end point) and for the two predeﬁned
covariates (visceral metastasis and ER status). No differences
in ORR were shown between anastrozole and letrozole for
ER-positive patients [131].
Considering ﬁrst-line treatment of metastatic disease,
letrozole signiﬁcantly improved outcome compared with
tamoxifen [132], while for anastrozole, the results were
conﬂicting [133–135]. In addition, indirect comparison
suggests improved efﬁcacy of letrozole versus anastrozole for
presurgical therapy [68–70]. While there is so far no major
difference between anastrozole and letrozole monotherapy with
respect to improvement of DFS compared with tamoxifen, over
100 months of follow-up, there is no evidence of any
improvement in OS for anastrozole compared with tamoxifen
[75]. In contrast, a nonsigniﬁcant trend (P = 0.08) for
improved survival is observed for letrozole [78] at a median
follow-up of 76 months. In contrast to patients in the ATAC
study, who completed assigned treatment without the option of
crossing over, patients in BIG 1–98 were subject to early
unblinding of the treatment code, resulting in 40% of
patients on tamoxifen monotherapy deciding to switch to
letrozole [78]. This further highlights potential
differences between anastrozole and letrozole with respect to
OS beneﬁts.
A similar comparison with respect to biochemical efﬁcacy is
not possible between anastrozole or letrozole on the one hand
and exemestane on the other as no head-to-head comparison of
aromatase inhibition or estrogen suppression between
nonsteroidal and steroidal aromatase inhibitors has been carried
out. Notably, there is clear evidence of a lack of cross-resistance
between nonsteroidal compounds and exemestane; the evidence
and potential mechanisms are discussed in detail elsewhere
[136]. Indeed, exemestane was as effective as fulvestrant among
patients failing nonsteroidal third-generation aromatase
inhibitors [137]. Thus, another question for future studies
may be the potential beneﬁt of sequential treatment with
steroidal and nonsteroidal aromatase inhibitors in the
adjuvant setting.
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